Slide 1: Interim report Q2 / 2022
Interim report Q2 / 2022 2022-07-15 Vitrolife AB (publ) Thomas Axelsson, CEO Patrik Tolf, CFO
Slide 2: Together for successful growth
Together for successful growth Second quarter Sales Organic growth Growth Pro forma excluding Covid-19 829 MSEK 18% 14% +117% in SEK In local currencies In local currencies Gross margin EBITDA Earnings per share 56.8% 273 MSEK 0.96 SEK (55.2 % Pro forma) Margin 32.9% (32.8% Pro forma) +22% YTD Sales
Slide 3: Sales and growth per market region
Sales and growth per market region Total Q2 growth rate (local currencies) 241% 53% 73% 85% 99% Organic growth (pro forma excl 13% 0% 41% 32% 14% Covid-19 testing, in local currencies) Sales (MSEK) 296 286 143 104 829 Share of 36% 35% 17% 13% Vitrolife’s sales 3 Vitrolife
Slide 4: Consumables business area
Consumables business area 24% 348 15% In local currencies 307 280 284 284 249 254 243 2% 3% Americas EMEA 39% 37% Asia Japan Pacific Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2020 2021 2022 Net sales MSEK 4 Vitrolife
Slide 5: Technologies business area
Technologies business area 37% 141 136 140 29% In local currencies 129 122 114 102 174% -9% 71 Americas EMEA 80% 55% Asia Japan Pacific Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2020 2021 2022 Net sales MSEK 5 Vitrolife
Slide 6: Genetic Services business area
Genetic Services* business area 21% 337 7% in local currencies 296 293 278 274 257 246 218 10% 2% Americas EMEA 16% 2% Asia Japan Pacific Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2020 2021 2022 Net sales MSEK 6 *Genetic Services excluding business related to Covid-19 Vitrolife
Slide 7: Together for successful growth
Together for successful growth Focus on fertility journey Customer offering Down-scaling of operations 7 Vitrolife
Slide 8: Q2 financial highlights
Q2 financial highlights 829 MSEK 696 Net sales of SEK 829 million (382) • Increase of 99% in local currencies including acquired revenue of SEK 341 million 314 470 • Growth on pro forma basis is 14% in local currencies excluding Covid-19 testing. 384 147 273 Gross income of SEK 470 million (237) 228
Slide 9: Net sales
Net sales 70 MSEK 91 28 314 829 696 382 Net sales Genetic Pro forma Covid-19 Sales growth Exchange Net sales 21Q2 Services Net sales test growth rates 22Q2 21Q2 9 Vitrolife
Slide 10: EBITDA
EBITDA MSEK 44 169 32.9% 277 75 35.2% 273 134 21Q2 GP from Gross OPEX D&A 22Q2 Net sales Income% 2021, Q2 2022, Q2 Growth EBITDA per share, SEK 1.24 2.01 +63% 10 Vitrolife
Slide 11: OPEX
OPEX +18% MSEK 295 249 123 • Normalised business activities 295 • Non-core operations 126 21Q2 22Q2 Proforma Genetic Services Vitrolife 11 Vitrolife
Slide 12: Key financials and pro forma
Key financials and pro forma 2022 2021 2021 Q2 Pro Delta Pro 2022 Q1- 2021 Q2 Q2 forma forma Q2 Q1-Q2 Sales, MSEK 829 382 696 +133 1,581 761 Gross Margin, % 57% 62% 55% +2ppt 56% 64% Adj. Gross Margin, %* 59% 63% 59% 0ppt 59% 65% Adjusted EBITDA, MSEK** 273 145 228 +45 501 311 Adjusted EBITDA, %** 3
Slide 13: Management comments
Management comments Strong growth IVF consolidation impact Americas now largest market region MDR for Technologies Vitrolife A/S Focus on fertility business 13 Vitrolife
Slide 14: Long-term market growth 5-10%
Long-term outlook Broadening the product and service offering Long-term market growth 5-10% in monetary terms Expansion of sales 14 Vitrolife
Slide 15: Q/A Session
Q/A Session Contact: Thomas Axelsson, CEO, taxelsson@vitrolife.com, +46 31 721 80 01 Patrik Tolf, CFO, ptolf@vitrolife.com, +46 31 766 90 21 Vitrolife
Slide 16: Disclaimer
DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i